Etanercept, a TNF inhibitor, has shown some promise in animal and cell culture models reducing cytokine release, preventing neurotoxic effects of TNF-α on dopaminergic cells and reducing caspase 3 activity [195–198], but had either limited or no benefits in trials in AD [199–201]. This evidence concerns the gene CASP3 and Alzheimer disease.